Navigation Links
Luminex Corporation Reports Record 2nd Quarter 2015 Results

AUSTIN, Texas, Aug. 3, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the second quarter ended June 30, 2015.  Financial and operating highlights for the quarter include the following:

  • Increased second quarter 2015 revenue by 6 percent to $58.9 million, over the second quarter of 2014.
  • Grew second quarter 2015 assay revenue by 22 percent to $24.2 million over results from the second quarter of 2014.
  • Increased Q2 2015 royalty revenue by 17 percent to $11.1 million over the second quarter of 2014.
  • Increased gross profit margin to 73 percent for the second quarter of 2015, up 4 points from the second quarter of 2014. 
  • Settled the litigation with Enzo Life Sciences, Inc. ("Enzo"), resulting in an expense of $7.1 million. The after-tax impact of the settlement decreased second quarter net earnings by approximately $0.12 per diluted share.
  • Delivered GAAP net income for the second quarter of $2.6 million, including the effect of the litigation settlement, or $0.06 per diluted share. Non-GAAP net income for the second quarter was $11.6 million, or $0.27 per diluted share (see Non-GAAP reconciliation).
  • Improved in operating profit for the quarter by over 100% as a result of expanding revenues and expense control
  • Submitted 510(k) applications to the FDA for approval of the ARIES® System and ARIES® HSV 1&2 Assay in July after the second quarter's close. 
  • "Our second quarter results reflect the Company's strong performance across its business, including achieving the highest level of quarterly revenue in the Company's history.  In particular both our molecular diagnostic assay franchise and royalty revenues contributed significantly to that success.  Accompanying the increase in revenues were excellent margins, significant profitability and positive cash flow," said Homi Shamir, President and Chief Executive Officer of Luminex. "We are also very pleased with the progress achieved this year in advancing our pipeline of transformational products, highlighted by the FDA submission in early July of our sample-to-answer platform, ARIES, and our first assay, HSV 1&2.  We currently expect FDA approval before year-end and are accelerating our preparations for the commercial launch of ARIES as well as preparing for additional assay submissions to the FDA."

     REVENUE SUMMARY(in thousands, except percentages) Three Months EndedJune 30,Variance20152014($)(%)(unaudited)System sales

    $(1,761)-21%Consumable sales

    11,87812,629(751)-6%Royalty revenue

    11,0739,4761,59717%Assay revenue

    24,23819,8864,35222%All other revenue

    5,1855,337(152)-3%$  58,917$  55,632$ 3,2856%Six Months EndedJune 30,Variance20152014($)(%)(unaudited)System sales

    $  12,507$  14,704$(2,197)-15%Consumable sales

    21,77425,397(3,623)-14%Royalty revenue

    21,77519,5252,25012%Assay revenue

    49,68441,5468,13820%All other revenue

    10,91811,021(103)-1%$116,658$112,193$ 4,4654% 

    Additional Financial Highlights:

  • Infectious disease assay sales were approximately 66 percent of total assay sales for the quarter and genetic testing assays were 34 percent.
  • Royalty revenues reflect total royalty-bearing end-user sales for the quarter of $122.0 million.
  • 234 multiplexing analyzers were shipped during the quarter, which included 119 MAGPIX systems, 94 LX systems, and 21 FLEXMAP 3D systems.
  • Cash and investments at quarter-end totaled $127.1 million.
  • Days sales outstanding (DSO) was 34 days at quarter-end.
  • FINANCIAL OUTLOOK AND GUIDANCE The Company updates its revenue guidance range for the full-year 2015 to between $232 million and $236 million and anticipates third quarter 2015 revenue to be between $56 million and $58 million.

    CONFERENCE CALL Management will host a conference call at 3:30 p.m. CDT/4:30 p.m. EDT, Monday, August 3, 2015 to discuss the operating highlights and financial results for the second quarter ended June 30, 2015. The conference call will be webcast live and may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex' or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; the development progress of our pipeline products, including ARIES and NxTAG products, market acceptance of our products, including instruments, consumables and assays, regulatory clearance of our products; the ability of our investment in current initiatives and new products to drive long-term value for our shareholders; and, projected 2015 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex' actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology in development, including ARIES and NxTAG, the uncertainty relating to increased focus on direct sales to the end user, dependence on strategic partners for development, commercialization and distribution of products, concentration of Luminex' revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex' technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges, the timing of and process for regulatory approvals, the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex' partners and end users and their ability to finance purchases of Luminex' products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of Luminex' assay products, Luminex' ability to obtain and enforce intellectual property protections on Luminex' products and technologies, risks and uncertainties associated with implementing Luminex' acquisition strategy, including Luminex' ability to obtain financing, Luminex' ability to integrate acquired companies or selected assets into Luminex' consolidated business operations, and the ability to recognize the benefits of Luminex' acquisitions, reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, changes in principal members of Luminex' management staff, potential shortages, or increases in costs, of components or other disruptions to Luminex' manufacturing operations, competition and competitive technologies utilized by Luminex' competitors, Luminex' ability to successfully launch new products in a timely manner, Luminex' increasing dependency on information technology to enable Luminex to improve the effectiveness of Luminex' operations and to monitor financial accuracy and efficiency, the implementation, including any modification, of Luminex' strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, and risks relating to Luminex' foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex' Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2015 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

     LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)June 30,December 31,20152014(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $   111,064$
    Short-term investments

    10,003-Accounts receivable, net

    22,17728,272Inventories, net

    32,59836,616Deferred income taxes

    6,21712,203Prepaids and other

    10,6728,235Total current assets

    192,731177,020Property and equipment, net

    47,90339,945Intangible assets, net

    54,70456,382Deferred income taxes

    15,12115,400Long-term investments



    2,9493,185Total assets

    $   369,032$
    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    Accrued liabilities

    17,30514,118Deferred revenue

    4,4104,407Total current liabilities

    29,76030,366Deferred revenue


    4,7634,869Total liabilities

    36,64037,532Stockholders' equity:Common stock

    4242Additional paid-in capital

    312,073309,424Accumulated other comprehensive loss

    (1,077)(744)Retained earnings

    21,35411,272Total stockholders' equity

    332,392319,994Total liabilities and stockholders' equity

    $   369,032$
     LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedSix Months EndedJune 30,June 30,2015201420152014(unaudited)(unaudited)Revenue

    $ 55,632$ 116,658$ 112,193Cost of revenue

    15,64717,48533,16934,092Gross profit

    43,27038,14783,48978,101Operating expenses:Research and development

    11,51011,30821,65522,392Selling, general and administrative

    21,02520,97040,50440,415Amortization of acquired intangible assets

    7769651,6781,985Restructuring costs

    -133-353Total operating expenses

    33,31133,37663,83765,145Income from operations

    9,9594,77119,65212,956Interest expense from long-term debt

    ---(6)Other income, net

    57(1)951(20)Settlement of litigation

    (7,100)-(7,300)-Income before income taxes

    2,9164,77013,30312,930Income tax expense

    (287)(45)(3,221)(2,239)Net income

    $  4,725$  10,082$  10,691Net income per share, basic

    Shares used in computing net income per share, basic

    42,09341,56041,98441,384Net income per share, diluted

    Shares used in computing net income per share, diluted

    42,29042,12542,14641,863 LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedSix Months EndedJune 30,June 30,2015201420152014(unaudited)(unaudited)Cash flows from operating activities:Net income

    $   4,725$  10,082$ 10,691Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    3,1243,6076,3227,535Stock-based compensation

    3,0902,8014,6694,430Deferred income tax expense

    5,1541,8426,0312,520Excess income tax expense from employee stock-based awards

    991-991-Loss (gain) on sale or disposal of assets

    212178(681)183Non-cash restructuring charges


    50(140)(103)(332)Changes in operating assets and liabilities:Accounts receivable, net

    2,140(478)6,0863,539Inventories, net

    1,122(623)4,050(1,522)Other assets

    (2,717)(295)(2,393)37Accounts payable

    (2,932)476(3,774)(2,105)Accrued liabilities

    8,077(2,081)388(4,515)Deferred revenue

    (383)(209)(176)7Net cash provided by operating activities

    20,55710,22731,49221,664Cash flows from investing activities:Purchases of available-for-sale securities

    ---(2,996)Sales and maturities of available-for-sale securities

    -1,516-4,513Purchase of property and equipment

    (3,670)(3,150)(12,568)(6,255)Proceeds from sale of assets

    -3989339Acquired technology rights

    (25)(64)(202)(64)Net cash used in investing activities

    (3,695)(1,659)(11,877)(4,763)Cash flows from financing activities:Payments on debt

    -(1,621)-(1,621)Proceeds from employee stock plans and issuance of common stock

    3082,3787133,480Excess income tax expense from employee stock-based awards

    (991)-(991)-Net cash (used in) provided by financing activities

    (683)757(278)1,859Effect of foreign currency exchange rate on cash

    (22)(1)3326Change in cash and cash equivalents

    16,1579,32419,37018,786Cash and cash equivalents, beginning of period

    94,90777,38691,69467,924Cash and cash equivalents, end of period

    $111,064$ 86,710$111,064$ 86,710 LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands, except per share amounts)Three Months EndedSix Months EndedJune 30,June 30,2015201420152014(unaudited)(unaudited)Income from operations

    $  9,959$ 4,771$ 19,652$
    Stock-based compensation

    3,0902,8014,6694,430Amortization of acquired intangible assets

    7769651,6781,985Costs associated with legal proceedings

    1838106201,600Severance costs

    157-19445Restructuring costs

    -510-1,320Adjusted income from operations

    $ 14,165$ 9,857$ 26,813$
    Interest expense from long-term debt

    ---(6)Other income, net

    57(1)951(20)Gain on sale of cost method equity investment

    --(892)-Income tax expense

    (287)(45)(3,221)(2,239)Income tax effect of above adjusting items

    (2,343)(320)(2,473)(708)Income tax benefit from intercompany debt cancellation

    -(994)-(994)Adjusted net income

    $ 11,592$ 8,497$ 21,178$
    Adjusted net income per share, basic

    $  0.20$
    Shares used in computing adjusted net income per share, basic

    42,09341,56041,98441,384Adjusted net income per share, diluted

    $  0.20$
    Shares used in computing adjusted net income per share, diluted


    The Company makes reference in this release to "non-GAAP operating income" and "non-GAAP net income" which excludes stock-based compensation expense, amortization of acquired intangible assets and the impact of costs associated with legal proceedings, which are unpredictable and can vary significantly from period to period, including costs associated with litigation against ENZO Life Sciences, Inc. and Irori Technologies, Inc. discussed in the Legal Proceedings section of our previously filed 10-K and 10-Qs and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. In addition, the Company's management uses such non-GAAP measures internally to evaluate and assess its core operations and to make ongoing operating decisions. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.



    Harriss T. CurrieMatthew ScaloSr. Vice President, Finance and Chief Financial OfficerSr. Director, Investor 

    Logo -


    SOURCE Luminex Corporation
    Copyright©2015 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
    2. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
    3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 29, 2013
    4. Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
    5. Luminex Corporation Reports Second Quarter 2013 Results
    6. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
    8. Luminex Corporation Reports Third Quarter 2013 Results
    9. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    10. Luminex Corporation Reports Second Quarter 2014 results
    11. Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
    Post Your Comments:
    (Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... The ... conclusion of its fundraising initiative for Feeding San Diego with a press ... The GHT Companies presents the final check of $5,000.00+ representing an overall donation result ...
    (Date:8/26/2020)... (PRWEB) , ... August 26, 2020 , ... ... and in-home air purification systems kill Coronavirus. While air purification technologies, including GreenTech ... including SARS and even Ebola, no air purification system has published results of ...
    (Date:8/26/2020)... ... August 26, 2020 , ... Hero Life Sciences announced today ... million 3 ply surgical disposable face masks and N95 respirators in its manufacturing plant ... the challenge that most Americans are facing in trying to find quality disposable face ...
    Breaking Medicine Technology:
    (Date:9/3/2020)... ... 03, 2020 , ... The growing adoption of artificial intelligence ... Virtual Conference, a two-day virtual event for radiology professionals that will be hosted ... follow-up to's successful virtual event in spring 2020, in which thousands of ...
    (Date:9/1/2020)... ... 01, 2020 , ... Board certified plastic surgeon Sepideh Saber, ... will be the first to bear her name, Dr. Saber has regularly performed ... as well as rhinoplasty, facial rejuvenation, and many more in association with several ...
    (Date:8/31/2020)... ... August 31, 2020 , ... ... are joining biomedical engineers from Carnegie Mellon University (CMU) to develop a new ... who have undergone open heart surgery. , The AGH/CMU team was recently awarded ...
    (Date:8/31/2020)... ... August 31, 2020 , ... Genesis Chiropractic Software ... today the launch of its integrated, HIPAA compliant, telehealth solution, available to US-based ... in under 90 seconds. , According to the U.S. Department of Health ...
    (Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give ... is donating 10 percent of each hotel room booked with a special new rate ... & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any ...
    Breaking Medicine News(10 mins):